Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $32.0 million.

  • Catalyst Pharmaceuticals' Other Operating Expenses rose 11.80% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year increase of 20.08%. This contributed to the annual value of $106.2 million for FY2024, which is 25.66% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Other Operating Expenses stood at $32.0 million for Q3 2025, which was up 6.81% from $30.0 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Other Operating Expenses ranged from a high of $32.0 million in Q3 2025 and a low of $4.5 million during Q2 2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Other Operating Expenses averaged around $25.5 million, with its median value being $24.9 million (2023).
  • Data for Catalyst Pharmaceuticals' Other Operating Expenses shows a peak YoY surged of 179.75% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Other Operating Expenses stood at $7.3 million in 2021, then soared by 60.25% to $11.8 million in 2022, then surged by 111.19% to $24.9 million in 2023, then rose by 24.61% to $31.0 million in 2024, then rose by 11.80% to $32.0 million in 2025.
  • Its Other Operating Expenses was $32.0 million in Q3 2025, compared to $30.0 million in Q2 2025 and $27.3 million in Q1 2025.